The company reported top line interim 8-week Phase I clinical results of LPCN 1144 showing liver fat reductions compared to placebo.
Testosterone treatment can be a game changer in making the first cure on the market for NAFLD.
LPCN 1144's market opportunity is not fully priced in the current stock price.
Phase I LPCN 1144 Clinical Study
Lipocine (LPCN) reported the 8-week top line interim result from Liver Fat Study using magnetic resonance imaging, proton density fat fraction (“MRI-PDFF”) technique on January 17, 2019.